ZANAGLIO, CAMILLA
 Distribuzione geografica
Continente #
NA - Nord America 1.170
EU - Europa 504
AS - Asia 290
AF - Africa 3
OC - Oceania 2
SA - Sud America 2
Totale 1.971
Nazione #
US - Stati Uniti d'America 1.159
IT - Italia 182
SG - Singapore 114
CN - Cina 102
UA - Ucraina 92
DE - Germania 61
FI - Finlandia 43
HK - Hong Kong 28
IE - Irlanda 28
TR - Turchia 25
RU - Federazione Russa 23
SE - Svezia 23
GB - Regno Unito 17
CZ - Repubblica Ceca 15
IN - India 12
CA - Canada 10
BE - Belgio 8
FR - Francia 6
AU - Australia 2
BR - Brasile 2
GR - Grecia 2
JP - Giappone 2
MY - Malesia 2
NL - Olanda 2
AZ - Azerbaigian 1
EG - Egitto 1
IR - Iran 1
JO - Giordania 1
KR - Corea 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
MX - Messico 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 1.971
Città #
Fairfield 193
Chandler 107
Singapore 99
Ashburn 87
Jacksonville 75
Seattle 72
Woodbridge 70
Wilmington 69
Ann Arbor 66
Cambridge 54
Houston 51
Princeton 51
New York 47
Helsinki 42
Beijing 39
Brescia 39
Hong Kong 28
Dublin 26
Istanbul 20
Shanghai 18
Boardman 15
Brno 14
Moscow 13
Des Moines 12
Pune 11
Munich 9
Nanjing 9
Brussels 8
Los Angeles 8
Shenyang 7
Toronto 7
Genoa 6
Jinan 6
Milan 6
San Diego 6
Bosio 5
Darfo 5
Kocaeli 5
Rome 5
Battipaglia 4
London 4
Tianjin 4
Alzano Lombardo 3
Bergamo 3
Bologna 3
Brendola 3
Dearborn 3
Santa Clara 3
Viterbo 3
Ancona 2
Casanova Lonati 2
Castleknock 2
Changsha 2
Chiswick 2
Falkenstein 2
Guangzhou 2
Hebei 2
Lovere 2
Melbourne 2
Ningbo 2
Nocera Superiore 2
Padova 2
Pescara 2
Shah Alam 2
São Paulo 2
Tokyo 2
Verdellino 2
Vicenza 2
Amman 1
Athens 1
Augusta 1
Baku 1
Brooklyn 1
Castiglione Delle Stiviere 1
Catania 1
Centurion 1
Chicago 1
Chieti 1
Civitavecchia 1
Espoo 1
Fiorenzuola D'arda 1
Gossolengo 1
Gîza 1
Haikou 1
Hangzhou 1
Hanover 1
Jiaxing 1
Kilburn 1
Kish 1
Kunming 1
La Spezia 1
Leawood 1
Lequio Tanaro 1
Mcallen 1
Mexico City 1
Nanchang 1
Nanterre 1
New Bedfont 1
Newark 1
North York 1
Totale 1.513
Nome #
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 126
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 124
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 112
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 111
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 100
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 99
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 97
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 90
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 88
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 88
Advances in CMV Management: A Single Center Real-Life Experience 84
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 76
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 75
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 72
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 69
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 68
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 63
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 62
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 61
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 58
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 56
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 52
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 51
dsDNA from extracellular vesicles (EVs) in adult AML 50
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 46
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 38
Totale 2.016
Categoria #
all - tutte 12.125
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.125


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020274 0 0 0 0 0 28 25 29 51 78 27 36
2020/2021555 14 32 19 95 30 77 29 60 52 77 40 30
2021/2022265 21 15 3 26 14 25 11 20 14 45 16 55
2022/2023292 38 15 12 20 22 54 2 49 44 7 16 13
2023/2024308 17 4 35 16 19 85 11 9 46 1 4 61
2024/2025231 13 18 0 94 56 50 0 0 0 0 0 0
Totale 2.016